IP Library › Granted Patent US 12,195,537
Granted Patent B2
US 12,195,537 · App. 17/296,752 · Granted Jan 14, 2025

Anti-4-1BB antibody and use thereof

Inventors: Eunyoung Park (Seongnam-si, KR); Yangsoon Lee (Seongnam-si, KR); Hyejin Chung (Seongnam-si, KR); Uijung Jung (Seongnam-si, KR); Youngdon Pak (Seongnam-si, KR); Jun Hyun Jeong (Seongnam-si, KR); Yeunju Kim (Seongnam-si, KR); Seawon Ahn (Seongnam-si, KR); Byungje Sung (Seongnam-si, KR)
Assignee: ABL BIO, INC.
C07K16/2827A61P35/00C07K16/2878C07K16/468C07K2317/21C07K2317/24C07K2317/31C07K2317/34C07K2317/565C07K2317/622C07K2317/64C07K2317/75C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,195,537
App. No.
17/296,752
Granted
Jan 14, 2025
Kind
B2
Abstract

Provided is an anti-4-1BB antibody or an antigen-binding fragment thereof, and uses thereof.

Claims (37)

1. An isolated anti-tumor necrosis factor receptor superfamily member 9 (anti-4-1BB) antibody or an antigen-binding fragment thereof, wherein (a) the anti-4-1BB antibody or (b) the anti-4-1BB antibody antigen-binding fragment comprises:

(a) a heavy chain complementarity determining region 1 (CDR-H1) of SEQ ID NO: 1, a heavy chain complementarity determining region 2 (CDR-H2) of SEQ ID NO: 4, a heavy chain complementarity determining region 3 (CDR-H3) of SEQ ID NO: 7, a light chain complementarity determining region 1 (CDR-L1) of SEQ ID NO: 12, a light chain complementarity determining region 2 (CDR-L2) of SEQ ID NO: 14, and A light chain complementarity determining region 3 (CDR-L3) of SEQ ID NO: 16;

(b) a CDR-H1 of SEQ ID NO: 1, a CDR-H2 of SEQ ID NO: 4, a CDR-H3 of SEQ ID NO: 8, a VL CDR1 of SEQ ID NO: 12, a VL CDR2 of SEQ ID NO: 14, and a VL CDR3 of SEQ ID NO: 16;

(c) a CDR-H1 of SEQ ID NO: 1, a CDR-H2 of SEQ ID NO: 4, a CDR-H3 of SEQ ID NO: 9, a VL CDR1 of SEQ ID NO: 12, a VL CDR2 of SEQ ID NO: 14, and a VL CDR3 of SEQ ID NO: 16;

(d) a CDR-H1 of SEQ ID NO: 2, a CDR-H2 of SEQ ID NO: 5, a CDR-H3 of SEQ ID NO: 10, a VL CDR1 of SEQ ID NO: 12, a VL CDR2 of SEQ ID NO: 14, and a VL CDR3 of SEQ ID NO: 16; or

(e) a CDR-H1 of SEQ ID NO: 3, a CDR-H2 of SEQ ID NO: 6, a CDR-H3 of SEQ ID NO: 11, a VL CDR1 of SEQ ID NO: 13, a VL CDR2 of SEQ ID NO: 15, and a VL CDR3 of SEQ ID NO: 17.

2. The anti-4-1BB antibody or an antigen-binding fragment thereof according to claim 1 , wherein (a) the anti-4-1BB antibody or (b) the anti-4-1BB antibody antigen-binding fragment comprises:

(1) a heavy chain variable region of SEQ ID NO: 18, and a light chain variable region of SEQ ID NO: 24;

(2) a heavy chain variable region of SEQ ID NO: 19, and a light chain variable region of SEQ ID NO: 24;

(3) a heavy chain variable region of SEQ ID NO: 20, and a light chain variable region of SEQ ID NO: 24;

(4) a heavy chain variable region of SEQ ID NO: 19, and a light chain variable region of SEQ ID NO: 25;

(5) a heavy chain variable region of SEQ ID NO: 20, and a light chain variable region of SEQ ID NO: 25;

(6) a heavy chain variable region of SEQ ID NO: 21, and a light chain variable region of SEQ ID NO: 24;

(7) a heavy chain variable region of SEQ ID NO: 22, and a light chain variable region of SEQ ID NO: 25;

(8) a heavy chain variable region of SEQ ID NO: 23, and a light chain variable region of SEQ ID NO: 26;

(9) a heavy chain variable region of SEQ ID NO: 57, and a light chain variable region of SEQ ID NO: 61;

(10) a heavy chain variable region of SEQ ID NO: 58, and a light chain variable region of SEQ ID NO: 61;

(11) a heavy chain variable region of SEQ ID NO: 58, and a light chain variable region of SEQ ID NO: 62;

(12) a heavy chain variable region of SEQ ID NO: 39, and a light chain variable region of SEQ ID NO: 62;

(13) a heavy chain variable region of SEQ ID NO: 59, and a light chain variable region of SEQ ID NO: 61; or

(14) a heavy chain variable region of SEQ ID NO: 60, and a light chain variable region of SEQ ID NO: 62.

3. The anti-4-1BB antibody or an antigen-binding fragment thereof according to claim 1 , wherein (a) the anti-4-1BB antibody or (b) the anti-4-1BB antibody antigen-binding fragment comprises:

(i) a heavy chain of SEQ ID NO: 27 and a light chain of SEQ ID NO: 33;

(ii) a heavy chain of SEQ ID NO: 28 and a light chain of SEQ ID NO: 33;

(iii) a heavy chain of SEQ ID NO: 29 and a light chain of SEQ ID NO: 33;

(iv) a heavy chain of SEQ ID NO: 28 and a light chain of SEQ ID NO: 34;

(v) a heavy chain of SEQ ID NO: 29 and a light chain of SEQ ID NO: 34;

(vi) a heavy chain of SEQ ID NO: 30 and a light chain of SEQ ID NO: 33;

(vii) a heavy chain of SEQ ID NO: 31 and a light chain of SEQ ID NO: 34; or

(viii) a heavy chain of SEQ ID NO: 32 and a light chain of SEQ ID NO: 35.

4. The anti-4-1BB antibody or an antigen-binding fragment thereof according to claim 1 , wherein anti-4-1BB antibody antigen-binding fragment is an anti-4-1BB single-chain variable fragment (scFv) comprising:

a light chain variable region of SEQ ID NO: 61 and a heavy chain variable region of SEQ ID NO: 57;

a light chain variable region of SEQ ID NO: 61 and a heavy chain variable region of SEQ ID NO: 58;

a light chain variable region of SEQ ID NO: 62 and a heavy chain variable region of SEQ ID NO: 58;

a light chain variable region of SEQ ID NO: 62 and a heavy chain variable region of SEQ ID NO: 39;

a light chain variable region of SEQ ID NO: 61 and a heavy chain variable region of SEQ ID NO: 59; or

a light chain variable region of SEQ ID NO: 62 and a heavy chain variable region of SEQ ID NO: 60.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 25, 2021
From: PARK, EUNYOUNG; LEE, YANGSOON; CHUNG, HYEJIN; JUNG, UIJUNG; PAK, YOUNGDON; JEONG, JUN HYUN; KIM, YEUNJU; AHN, SEAWON; SUNG, BYUNGJE
To: ABL BIO INC.
Reel/Frame 056343/0931 →
Continuity (2)
Provisional Application 62773239 · Nov 30, 2018
Related Publication 20220242961A1 · Aug 4, 2022
References Cited (32)
US 11891445B1 · Park · 2024 [cited by examiner]
US 20140178368A1 · Sharp et al. · 2014 [cited by applicant]
US 20160244528A1 · Gray et al. · 2016 [cited by applicant]
US 20170355756A1 · Julien · 2017 [cited by examiner]
US 20180258177A1 · Kwon et al. · 2018 [cited by applicant]
JP 2006500921 · 2006 [cited by applicant]
JP 2013544756 · 2013 [cited by applicant]
JP 2018527939 · 2018 [cited by applicant]
WO 2005035584 · 2005 [cited by applicant]
WO WO2008068048A2 · 2008 [cited by examiner]
WO 2012032433 · 2012 [cited by applicant]
WO 2017181034 · 2017 [cited by applicant]
WO 2017182672 · 2017 [cited by applicant]
WO 2017205745 · 2017 [cited by applicant]
WO 2018045110 · 2018 [cited by applicant]
Mariuzza et al. (Annu. Rev.Biophys. Biophys. Chem., 16:139-159, 1987) (Year: 1987). [cited by examiner]
Chester et al ( Blood, 131:49-57, 2018) (Year: 2018). [cited by examiner]
KIPO, PCT Search Report & Written Opinion of PCT/KR2019/016863 dated Mar. 24, 2020. [cited by applicant]
Sambrook et al., Molecular Cloning: A Laboratory Manual, 4th ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (2012). [cited by applicant]
Ausubel et al., Current Protocols in Molecular Biology, Greene Publishing Associates, Dec. 4, 2003 (ISBN: 047150338X). [cited by applicant]
Zheng-Rong Chen et al., “Therapeutic effects of antieB7-H3 antibody in an ovalbumin-induced mouse asthma model”, Ann Allergy Asthma Immunol 111 (2013) 276-281. [cited by applicant]
Russell et al., “Structural Features can be Unconserved in Proteins with Similar Folds”, J. Mol Biol., 244: 332-350 (1994). [cited by applicant]
John Devereux et al., “A comprehensive set of sequence analysis programs for the VAX”, 1984, Nucl. Acid Res. 12:387. [cited by applicant]
M.O. Dayhoff et al., “A Model of Evolutionary Change in Proteins”, 1978, Atlas of Protein Sequence and Structure 5:345-352. [cited by applicant]
Steven Henikoff et al., “Amino acid substitution matrices from protein blocks”, 1992, Proc. Natl. Acad. Sci. U.S.A. 89:10915-10919. [cited by applicant]
Saul B. Needleman et al., “A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins”, 1970, J. Mol. Biol. 48:443-453. [cited by applicant]
Songsivilai and Lachmann, “Bispecific antibody: a tool for diagnosis and treatment of disease”, 1990, Clin. Exp. Immunol. 79:315-321. [cited by applicant]
Sheri A. Kostelny et al., “Formation of a bispecific antibody by the use of leucine zippers.”, J Immunol 1992; 148:1547-1553. [cited by applicant]
Chothia and Lesk, “Canonical Structures for the Hypervariable Regions of Immunoglobulins”, J. Mol. Biol. 196:901-917 (1987). [cited by applicant]
Hye Young Yang et al., “Construction of a Large Synthetic Human scFv Library with Six Diversified CDRs and High Functional Diversity”, Mol. Cells OT, 225-235, Feb. 28, 2009. [cited by applicant]
EPO, Extended European Search Report of the corresponding European Patent Application No. 19890588.7. dated Jul. 28, 2022. [cited by applicant]
Segal, Neil H., et al. “Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody.” Clinical Cancer Research 23.8 (Oct. 18, 2016): 1929-1936. [cited by applicant]
Cited By (1)
US 12,577,313